Cryo-Cell International, Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David I. Portnoy
- Full Time Employees
- 82
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 700 Brooker Creek Boulevard Oldsmar FL United States of America 34677
- IPO Date
- Apr 4, 1994
- CIK
- 0000862692
- Website
- cryo-cell.com
- Similar Companies
- Business
- Cryo-Cell International, Inc. (NYSE American: CCEL) operates as a leader in the cord blood banking industry, specializing in the collection, processing, and cryogenic storage of umbilical cord blood and tissue stem cells for family use; it also manufactures PrepaCyte-CB, a proprietary processing system designed to optimize umbilical cord blood stem cell recovery. The company offers comprehensive services including cord blood banking, which preserves hematopoietic stem cells for potential treatments of blood disorders and cancers; cord tissue banking, storing mesenchymal stem cells from umbilical cord tissue for regenerative applications such as bone, muscle, and cartilage repair; and innovative options like C'elle for cryopreserving menstrual stem cells from women. Headquartered in Oldsmar, Florida, Cryo-Cell was founded in 1989 as the world's first private cord blood bank to separate and store stem cells in 1992, serving over 500,000 clients across 87 countries through its state-of-the-art, FDA-compliant facility that handles all processing, testing, and storage in-house. Cryo-Cell conducts its operations globally with a focus on expecting parents and families seeking long-term stem cell preservation, while advancing regenerative medicine through research collaborations and technology development; its reportable segments encompass cellular processing and cryogenic storage, PrepaCyte-CB manufacturing, and related product sales. Among its latest developments, Cryo-Cell maintains an exclusive collaborative license agreement with Duke University, established in February 2021, granting access to intellectual property, proprietary processes, and clinical data from The Marcus Center for Cellular Cures to support cord blood and tissue applications in treating conditions like autism, cerebral palsy, traumatic brain injuries, adult stroke, multiple sclerosis, osteoarthritis, and COVID-19, including plans for infusion clinics under the FDA's Expanded Access Program. The company continues to invest in technological infrastructure, allocating significant resources to R&D for advanced cryopreservation techniques and global expansion into emerging markets like Asia-Pacific, while reporting strong operational metrics such as 537,892 total stored specimens and 12 active research partnerships as of recent updates. In fiscal third quarter 2025, Cryo-Cell announced financial results underscoring its leadership in cord blood banking, with ongoing dividend payments and a focus on revenue growth from processing fees and recurring storage contracts.
Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks
Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Passes Below 200-Day Moving Average – What’s Next?
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Passes Below 200-Day Moving Average – Should You Sell?
Cryo-Cell Receives NYSE American Continued Listing Notice
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025
Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell?
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2025 Financial Results
Cryo-Cell International, Inc. Provides Dividend Update
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2025 Financial Results
Cord Blood Banking Leader Cryo-Cell Announces Cash Dividend
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2024
Cord Blood Banking Leader Cryo-Cell Announces Regular Quarterly Cash Dividend and Pause of Strategic Initiatives
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2024 Financial Results
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2023 Financial Results
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2023 Financial Results
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2023 Financial Results
Cryo-Cell International: A Stable Business Paired With An Upcoming Catalyst